Understanding Lymphoma in African Americans to Find Better Treatments
Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway Inhibitors
['FUNDING_R01'] · GEORGIA INSTITUTE OF TECHNOLOGY · NIH-11145031
This project aims to understand why a type of lymphoma affects African American patients differently and to find better ways to treat it.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGIA INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11145031 on ClinicalTrials.gov |
What this research studies
This project focuses on a type of blood cancer called non-Hodgkin's lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), which can be very aggressive. We know that African-American patients often have more challenging outcomes with DLBCL and are diagnosed at a younger age, with unique genetic changes in their tumors. To address this, researchers are creating tiny, lab-grown models of these lymphomas, called organoids, using cells from African-American patients. These organoids will help us learn more about the specific genetic changes in these lymphomas and test how well different targeted medications, called B cell receptor pathway inhibitors, work. The goal is to discover more effective treatments tailored to African-American patients.
Who could benefit from this research
Good fit: This foundational research is focused on understanding the specific characteristics of lymphomas in African-American patients, which could eventually benefit those diagnosed with diffuse large B-cell lymphoma (DLBCL) or marginal zone lymphomas (MZLs).
Not a fit: Patients with other types of cancer or those whose lymphoma does not involve the B cell receptor pathway may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new, more effective, and personalized treatment options for African-American patients with aggressive lymphomas.
How similar studies have performed: While targeted therapies for lymphoma exist, this approach of using patient-derived organoids to specifically study African-American lymphomas and test B cell receptor pathway inhibitors is a novel and promising strategy.
Where this research is happening
ATLANTA, UNITED STATES
- GEORGIA INSTITUTE OF TECHNOLOGY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SINGH, ANKUR — GEORGIA INSTITUTE OF TECHNOLOGY
- Study coordinator: SINGH, ANKUR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.